Equities research analysts expect Nuvectra Corp (NASDAQ:NVTR) to announce earnings of ($0.61) per share for the current quarter, according to Zacks. Two analysts have made estimates for Nuvectra’s earnings. The lowest EPS estimate is ($0.62) and the highest is ($0.59). Nuvectra posted earnings per share of ($0.87) during the same quarter last year, which would suggest a positive year-over-year growth rate of 29.9%. The company is scheduled to announce its next earnings report on Monday, November 4th.

On average, analysts expect that Nuvectra will report full-year earnings of ($2.44) per share for the current financial year, with EPS estimates ranging from ($2.64) to ($2.23). For the next financial year, analysts anticipate that the firm will report earnings of ($1.63) per share, with EPS estimates ranging from ($2.00) to ($1.25). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Nuvectra.

Nuvectra (NASDAQ:NVTR) last announced its quarterly earnings results on Wednesday, July 31st. The company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.19. The firm had revenue of $12.35 million for the quarter, compared to the consensus estimate of $12.42 million. Nuvectra had a negative return on equity of 58.23% and a negative net margin of 99.08%.

Several research firms have recently commented on NVTR. Zacks Investment Research downgraded Nuvectra from a “buy” rating to a “hold” rating in a research report on Wednesday. JMP Securities decreased their target price on Nuvectra to $10.00 and set an “outperform” rating on the stock in a research report on Thursday, August 1st. They noted that the move was a valuation call. ValuEngine raised Nuvectra from a “hold” rating to a “buy” rating in a research report on Thursday, October 10th. Finally, Piper Jaffray Companies decreased their target price on Nuvectra from $18.00 to $4.00 and set an “overweight” rating on the stock in a research report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $8.75.

Shares of Nuvectra stock traded up $0.30 on Thursday, hitting $1.79. The stock had a trading volume of 6,499,562 shares, compared to its average volume of 274,066. Nuvectra has a twelve month low of $1.24 and a twelve month high of $22.13. The business’s 50 day moving average is $1.57 and its two-hundred day moving average is $3.89. The company has a quick ratio of 4.42, a current ratio of 4.86 and a debt-to-equity ratio of 0.58. The stock has a market cap of $26.65 million, a price-to-earnings ratio of -0.56 and a beta of 0.70.

Institutional investors have recently bought and sold shares of the company. Acadian Asset Management LLC acquired a new position in shares of Nuvectra in the second quarter valued at approximately $35,000. SNS Financial Group LLC bought a new stake in shares of Nuvectra in the second quarter valued at approximately $36,000. Resources Investment Advisors LLC. bought a new stake in shares of Nuvectra in the second quarter valued at approximately $39,000. Tower Research Capital LLC TRC boosted its stake in shares of Nuvectra by 1,431.1% in the second quarter. Tower Research Capital LLC TRC now owns 13,030 shares of the company’s stock valued at $44,000 after buying an additional 12,179 shares during the period. Finally, Jefferies Group LLC bought a new stake in shares of Nuvectra in the second quarter valued at approximately $52,000. 78.10% of the stock is currently owned by institutional investors.

Nuvectra Company Profile

Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs.

Further Reading: What is the Current Ratio?

Get a free copy of the Zacks research report on Nuvectra (NVTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nuvectra (NASDAQ:NVTR)

Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.